NCT05015608View on ClinicalTrials.gov

Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

November 22, 2021

Primary Completion Date

December 15, 2025

Study Completion Date

December 30, 2025

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Savolitinib + Osimertinib

Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.

DRUG

Pemetrexed + Cisplatin /Carboplatin

Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)

Trial Locations (1)

210000

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY